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GPCRs through the keyhole: the role of protein flexibility in ligand 
binding to -adrenoceptors  
G protein-coupled receptors (GPCRs) are proteins of pharmaceutical importance, 
with over 30% of all drugs in clinical use targeting them. Increasing numbers of 
X-ray crystal (XRC) structures of GPCRs offer a wealth of data relating to ligand 
binding. For the -adrenoceptors (-ARs), XRC structures are available for 
human 2- and turkey 1-subtypes, in complexes with a range of ligands. While 
these structures provide insight into the origins of ligand structure-activity 
relationships (SARs), questions remain. The ligands in all published complexed 
XRC structures lack extensive substitution, with no obvious way the ligand-
binding site can accommodate β1-AR-selective antagonists with extended side-
chains para- to the common aryloxypropanolamine pharmacophore. Using 
standard computational docking tools with such ligands generally returns poses 
that fail to explain known SARs. Application of our Active Site Pressurization 
(ASP) modelling method to -AR XRC structures and homology models 
however, reveals a dynamic area in the ligand-binding pocket that, through minor 
changes in amino acid side chain orientations, opens a fissure between 
transmembrane (TM) helices H4 and H5, exposing intra-membrane space. This 
fissure, which we term the ‘keyhole’, is ideally located to accommodate extended 
moieties present in many high-affinity 1-AR-selective ligands; allowing the rest 
of the ligand structure to adopt a canonical pose in the orthosteric binding site. 
We propose the keyhole may be a feature of both 1- and 2-ARs, but that subtle 
structural differences exist between the two, contributing to subtype-selectivity. 
This has consequences for the rational design of future generations of subtype-
selective ligands for these therapeutically important targets. 
Keywords: GPCRs, beta adrenergic receptor, modelling, docking, active site 
pressurization, molecular dynamics, protein flexibility 
Abbreviations: GPCR, G protein-coupled receptor; ASP, Active Site 
Pressurization; XRC, X-ray crystallography; -AR, beta adrenergic receptor; 
T4L, T4 lysozyme; MD, molecular dynamics; TM, transmembrane; H1 – H7, 
helix number 1 through to 7; ECL, extracellular loop; ICL, intracellular loop; 
HBA, hydrogen bond acceptor; HBD, hydrogen bond donor; H-bond, hydrogen 
bond; SAR, structure-activity relationship; LJ, Lennard-Jones; SEM, standard 
error of the mean; PDB, Protein Data Bank; VdW, Van der Waals 
Introduction 
The now rapidly-increasing number of XRC structures of GPCRs is providing a wealth 
of data about the structural basis of the mechanism of action of these pharmaceutically 
very important molecules and how this is modulated by ligand binding.(Congreve, 
Langmead, Mason, & Marshall, 2011; Heifetz et al., 2015; Katritch, Cherezov, & 
Stevens, 2012; B. K. Kobilka, 2007; 2011; Parrill & Bautista, 2010; Tate, 2012; Topiol 
& Sabio, 2009; Venkatakrishnan et al., 2013)  In the case of -ARs, we now have 
crystal structures available for the human 2- and turkey 1-ARs in complexes with a 
range of agonists, antagonists, inverse agonists (Table 1) and a series of ligand sub-
fragments. In addition there are G-protein and nanobody-bound structures, as well as an 
oligomeric apo-receptor structure.(Bokoch et al., 2010; Cherezov et al., 2007; 
Christopher et al., 2013; Hanson et al., 2008; J. Huang, Chen, Zhang, & Huang, 2013; 
Miller-Gallacher et al., 2014; Moukhametzianov et al., 2011; Rasmussen et al., 2007; 
2011a; 2011b; Ring et al., 2014; Rosenbaum et al., 2011; Wacker et al., 2010; Warne, 
Edwards, Leslie, & Tate, 2012; Warne et al., 2011; 2008; Weichert et al., 2014; Zou, 
Weis, & Kobilka, 2012)  The holo/liganded structures reveal a consistent mode of 
interaction with the receptors whether the receptor is in its inactive (R) or active (R*) 
state (Figure 1). The orthosteric binding pockets of β1- and β2-ARs are almost identical. 
Of the amino acids that line the pocket the only difference evident is at position 7.35  
(Ballesteros-Weinstein numbering(Ballesteros & Weinstein, 1995)) where Phe359 in β1-
AR is replaced by Tyr308 in β2-AR.(B. K. Kobilka, 2011) The β2-AR XRCs indicate that 
Tyr308,7.35 can stabilise Asn293,6.55 via interhelical H-bonding, whereas Asn344,6.55 in β1-
AR does not have this stabilising feature and adopts a different rotamer position. As was 
originally indicated by mutagenesis studies(Baker, Proudman, Hawley, Fischer, & Hill, 
2008; Dixon et al., 1987; Strader et al., 1988; 1987; Strosberg, 1993), XRCs indicate 
that the essential ethanolamine core (coloured blue in Table 1 and Figure 1), present in 
all -AR ligands with the exception of dobutamine and its sub-fragments, makes salt-
bridge and hydrogen-bonded interactions with Asp3.32 and Asn7.39 respectively. 
(Cherezov et al., 2007; Christopher et al., 2013; Hanson et al., 2008; J. Huang et al., 
2013; Miller-Gallacher et al., 2014; Moukhametzianov et al., 2011; Rasmussen et al., 
2007; 2011a; 2011b; Ring et al., 2014; Rosenbaum et al., 2011; Wacker et al., 2010; 
Warne et al., 2008; 2011; 2012; Weichert et al., 2014; Zou et al., 2012) The 
ethanolamine nitrogen atom is protonated at physiological pH and the carbinol 
stereochemistry of the higher affinity isomer is as shown in Table 1. An extensive 
hydrogen-bonding network exists between the core and several further important 
residues (represented in Figure 1 as yellow arrows indicating the direction of H-bond 
donation). Tyr7.43 plays a role in stabilising Asp3.32 through an interhelical (H7-H3) H-
bond (shown as a purple arrow), and has potential to interact with the core 
ethanolamine. N-Substituents of the ethanolamine (‘tail’ groups) extend in the general 
direction of the entrance channel towards the extracellular surface, while moieties 
attached to the carbinol side of the core pharmacophore (‘head’ groups) occupy a large 
and rather hydrophobic pocket in which Phe6.52 and Phe5.32 are often involved in π-
stacking interactions and Val3.33 is known to be important.(Bokoch et al., 2010; 
Chelikani et al., 2007; Cherezov et al., 2007; Christopher et al., 2013; Hanson et al., 
2008; J. Huang et al., 2013; B. K. Kobilka, 2011; Lebon, Warne, & Tate, 2012; 
Moukhametzianov et al., 2011; Rasmussen et al., 2007; 2011a; 2011b; Rosenbaum et 
al., 2011; Wacker et al., 2010; Warne et al., 2008; 2011; 2012; Zou et al., 2012) The 
head group (coloured red in Tables 1 and 2 and Figure 1) largely determines whether 
the ligand is an agonist or antagonist (for the conventional G-protein signalling 
pathway). Biogenic amines such as adrenaline possess a catechol head group (1,2-
dihydroxyphen-4-yl) attached directly to the core ethanolamine, which forms H-bonds 
with Ser5.43 and Ser5.46 on H5, respectively. (Rasmussen et al., 2011a; 2011b; Ring et 
al., 2013; Rosenbaum et al 2011; Warne et al., 2011; Weichert et al., 2014)  These 
interactions draw H5 inwards towards the core, reducing the pocket size, and stabilising 
the active (R*) signalling state of the receptor. In contrast, the addition of a 
methyleneoxy spacer between the ethanolamine and the aromatic portion of the head 
group (i.e. to furnish the aryloxypropanolamine scaffold), pushes the aromatic portion 
of the head group deeper into the binding pocket. This reduces the necessary inward 
conformational movement of the receptor to maximize interaction with this portion of 
the ligand, and/or does not induce the specific rotamer states of both Ser5.42 and Ser5.46 
to fully facilitate movement of H5; resulting in an antagonist, inverse agonist, or partial 
agonist ligand. (Bokoch et al., 2010; Cherezov et al., 2007; Christopher et al., 2013; 
Hanson et al., 2008; J. Huang et al., 2013; B. K. Kobilka, 2011; Lebon et al., 2012; 
Moukhametzianov et al., 2011; Rasmussen et al., 2007; Wacker et al., 2010; Warne et 
al., 2008; 2011; 2012; Zou et al., 2012) 
The R groups attached to the head group (Figure 1) represent the potential for 
structural diversity; heteroaromatic ring systems are common (see Table 1). The green 
line indicates conserved π-π stacking between Phe6.52 and the common aromatic part of 
the head group, although if the ring system is larger, Phe5.32 located on extracellular loop 
2 (ECL2) can also contribute to π-π stacking (represented as dashed green line). Dashed 
yellow arrows indicate the general locations of previously observed ligand-dependent 
H-bonding between the β-ARs and antagonists (see references in Table 1 for details). 
The carbazole NH present in carazolol (1) and the indolic NH moieties of cyanopindolol 
(2) and iodocyanopindolol (3) can donate H-bonds to Ser5.42, whereas the benzofuran 
oxygen of (8) can also receive an H-bond from this residue. The nitrile groups of 
cyanopindolol (2) and iodocyanopindolol (3) can accept a weak H-bond from Thr5.34 
and Asn6.55. Furthermore, Asn6.55 can also form H-bonds with the morpholino oxygen of 
timolol (6) and ethoxy group of (8). The thiadiazole moiety present in timolol (6) can 
accept H-bonds from Thr3.37. The R1 group, or tail group (coloured black), can be 
extremely short or long and diverse (see Table 1). Examples of the latter have been 
associated with biased receptor signalling (signalling mediated through pathways others 
than the G-proteins)(Liu, Horst, Katritch, Stevens, & Wuthrich, 2012; Warne et al., 
2012) and subtype selectivity as longer tail groups have the potential to make 
interactions with the less conserved residues at the pocket entrance and extracellular 
surface of the receptor. (B. K. Kobilka, 2011) 
Table 1. -AR antagonist ligands that have been co-crystallised with a receptor to date. 
Compound 
ID 
-blocker 
ligandsa 
Structure 
(PDB codes)b 
Resolution 
(Å) 
Structurec 
(1) Carazolol 
Human 2-AR-
T4L construct 
(2RH1) 
Human 2-AR-
Fab construct 
(2R4R, 2R4S) 
Turkey 1-AR 
construct 
(2YCW) 
 
2.40(Cherezov et al., 2007) 
 
3.40(Rasmussen et al., 
2007) 
 
3.00(Moukhametzianov et 
al., 2011) 
 
 
(2) Cyanopindolol 
Turkey 1-AR 
construct 
(2VT4, 2YCX, 
2YCY, 4BVN) 
2.70(Warne et al., 2008), 
3.25(Moukhametzianov et 
al., 2011), 
3.15(Moukhametzianov et 
al., 2011), 2.10 (Miller-
Gallacher et al., 2014) 
 
(3) Iodocyanopindolol 
Turkey 1-AR 
construct 
(2YCZ) 
3.65(Moukhametzianov et 
al., 2011) 
 
(4) Bucindolol 
Turkey 1-AR 
construct 
(4AMI) 
3.20(Warne et al., 2012) 
 
(5) Carvedilol 
Turkey 1-AR 
construct 
(4AMJ) 
2.30(Warne et al., 2012) 
 
(6) Timolol 
Human 2-AR-
T4L construct 
(3D4S) 
2.80(Hanson et al., 2008) 
 
(7) ICI-118,551 
Human 2-AR-
T4L construct 
(3NY8) 
2.84(Wacker et al., 2010) 
 
(8) 
See Wacker et 
al.(Wacker et al., 
2010) (inverse 
agonist) 
Human 2-AR-
T4L construct 
(3NY9) 
2.84(Wacker et al., 2010) 
 
(9) Alprenolol 
Human 2-AR-
T4L construct 
(3NYA) 
3.16(Wacker et al., 2010) 
 
aLigands which stabilise reduced-signalling or non-signalling states of -ARs are 
classified as partial agonists, antagonists and inverse agonists; generally, they may be 
referred to as ‘-blockers’. They are also collectively referred to as antagonists within 
this manuscript. 
bThe ligands shown have been crystallised with engineered -ARs 
cThe essential ethanolamine core of each ligand is coloured blue, the head group is 
coloured red, and the tail group is coloured black. All ligands are represented as the 
higher affinity S-enantiomers. 
 
Although the XRC structure data thus gives invaluable insights into many aspects of the 
SARs of -AR ligands, it does not explain everything. In particular, there are a number 
of antagonists that feature longer head group extensions than any of the ligands in 
published crystal structures. Examples are acebutolol (10), betaxolol (11), esmolol (12), 
bisoprolol (13), CGP20712A (14), LK 204-545 (16), and 1-(2-(3-(4-(2-
(cyclopropylmethoxy)ethoxy)phenoxy)-2-hydroxypropylamino)ethyl)-3-(4- 
hydroxyphenyl)urea  (15)(Mistry et al., 2013); these are shown in Table 2.  
  
Table 2. “Extended” antagonist structures that exhibit mild to moderate 1-AR 
selectivity 
Compound 
ID 
-blocker 
ligands 
Human 1-AR/2-AR 
selectivity: 3H-
CGP12177 whole-cell 
binding affinities (log 
Kd) (Baker, 2005; 2010; 
Wacker et al., 2010) 
Structurea 
1-AR 
affinity 
2-AR 
affinity 
Ratio 
1:2 
(10) Acebutolol -6.46 -6.08 2.4 
 
(11) Betaxolol -8.21 -7.38 6.8 
 
(12) Esmolol -6.73 -5.73 10 
 
(13) Bisoprolol -7.83 -6.70 13.5 
 
(14) CGP20712A -8.81 -6.11 501.2 
 
(15) 
See Mistry 
et al.(Mistry 
et al., 2013) 
-7.59 -4.65 871.0 
 
(16) LK 204-545 -8.38 -5.00 2398.8 
 
aThe ethanolamine core of each ligand is coloured blue, the head group is coloured red, 
and the tail group is coloured black. 
 
One particular feature of many of these ligands is their increased selectivity, compared 
to less extensive ligands, for the 1-AR over the 2-AR (Table 2). As part of our studies 
into the design and development of subtype-selective ligands, we attempted to dock 
these molecules to the known -AR XRC structures, and homology models of the 
human 1- and 2-AR that we have built from them. In all cases, using conventional 
docking methods (Glide), we found it almost impossible to generate poses for these 
ligands that resembled the canonical one, due to the inability of the extended ligand 
head groups to fit within the confines of the conventional binding pocket. Many of the 
poses generated failed to show convincing interactions for the ethanolamine core and 
failed to explain other aspects of known SARs. On this basis we concluded that it was 
worth investigating an alternative hypothesis for the activity of such ligands – not that 
they adopted an alternative pose in the -AR ligand binding site, but that this site in fact 
has as-yet unrecognised structural plasticity and can distort to accommodate the ligands 
whilst allowing them to maintain an otherwise conventional pose. 
We envisaged that our Active Site Pressurization (ASP) method (Withers, 
Mazanetz, Wang, Fischer, & Laughton, 2008) would be ideal for this investigation. ASP 
simulates the process of injecting particles into a protein cavity rather like injecting a 
resin into a mould. The injection process takes place under pressure, so once the empty 
volume is filled, further expansion can take place in the most energetically favourable 
directions. The method does not involve making any prior decisions as to what the 
modes of deformation might be, nor does it require one to make any assumptions as to 
the size or shape of the molecule that will fit into the volume. Here we present the 
results of that study. 
Remarkably, our findings suggest that the hydrophobic pocket in both the 1- 
and 2-AR contains a weak point in its wall between H4 and H5, such that ASP leads to 
the creation of a fissure in the pocket that leads out to the intra-membrane space. This 
fissure, which we term the ‘keyhole’, has exactly the position, dimensions, and 
chemical characteristics to permit ligands with extended head groups to bind to the 
receptors in the canonical orientation. Indeed, several of the -AR XRC structures 
corroborate our ASP findings. Though not specifically mentioned by the authors of the 
publications, 11 of the 16 1-AR structures and 1 of the 16 2-AR structures do in fact 
exhibit a keyhole, as a result of minor side-chain and backbone adjustments which to a 
large extent are as predicted by our ASP studies.  
One of the few residues within 5 Å of the conventional binding pocket that is not 
conserved between the 1- and 2-AR is located at position 4.56 (Val189 and Thr164 in 
1- and 2-AR respectively) and is one of five main residues which line the keyhole; it 
also happens to be the site of the naturally occurring 2-AR Thr164Ile 
polymorphism.(Green, Cole, Jacinto, Innis, & Liggett, 1993) This mutation results in 
reduced agonist affinity and slightly lower receptor basal activity.(Green et al., 1993; 
Green, Rathz, Schuster, & Liggett, 2001) Our findings suggest that this residue may 
well play an important role in ligand selectivity. 
Methods 
1. Homology modelling 
Homology models were built using Prime(Green et al., 1993; 2001; Suite 2012: Prime, 
version 3.1, Schrödinger LLC New York, NY, 2012) and refined using Maestro(Suite 
2012: Maestro, version 9.3, Schrödinger, LLC, New York, NY, 2012) and the Prime 
loop refinement module(Jacobson, Friesner, Xiang, & Honig, 2002; Jacobson, Pincus, 
& Rapp, 2004). The β2-T4L construct containing the ligand carazolol (1) (PDB code 
2RH1) was reverse engineered to more accurately represent the human 2-AR wild-type 
sequence; chain B of the 2YCW XRC structure was used to model the human 1-AR 
sequence as it also contains carazolol (1), and despite being a thermostabilised avian 
construct (36-m23(Jacobson et al., 2002; 2004; Moukhametzianov et al., 2011)) with 
slightly different pharmacology to the human 1-AR,(Baker, Proudman, & Tate, 2011) 
it shares higher homology with human 1-AR than human 2-AR (2RH1) does. The 
wild-type human 1-AR and 2-AR sequences were obtained from NCBI(National 
Center for Biotechnology Information. Protein Database) and aligned to both crystal 
templates (2RH1 and 2YCW) using Prime. The alignment was checked using 
ClustalW(Larkin et al., 2007) and found to be in good agreement. The N-terminus of the 
1-AR sequence was truncated by 49 residues, and 84 residues were removed from the 
C-terminus. Due to the limitations of loop modelling tools, no attempt was made to 
model the full length of the third intracellular loop, rather 45 residues were removed and 
the ends (Asp259 and Arg305) were joined to form a pseudo-loop. For 2-AR the 
Asn187Glu mutation in ECL2, which had been employed to eliminate a glycosylation 
site in the 2-T4L crystal construct, was reversed, the T4-lysozyme was removed and 
the third intracellular loop was replaced. This loop, despite being long, is still 
considerably shorter than that of the 1-AR isoform, and was successfully modelled 
using Prime’s ultra-extended loop refinement tool with the addition of an Atom 
Specification Language (ASL) placed implicit membrane to exclude predictions that 
were not outside the membrane region. Unresolved N- and C-terminal regions were 
omitted as with the 1-AR model, resulting in a 2-AR model that spanned from Thr25 
to Cys393 (inclusive). The template ligand carazolol (1) was preserved in both models 
but no water molecules or other heteroatoms were retained or added. 
2. Active Site Pressurization 
ASP was performed using the approach described by Withers et al.,(Withers et al., 
2008) re-implemented in code written in the modelling language NAB.(Macke & Case, 
2009) Grids for the insertion of the Lennard-Jones (LJ) particles were built, with a 1.1 Å 
spacing, to encompass the region occupied by the carbazole group present in carazolol 
(1), plus a 7.0 Å margin along all axes beyond it. The starting seed particle from which 
the LJ cast grew outwards was chosen to correspond to the ether oxygen atom of 
carazolol (1) before the ligand was removed. The Amber ff99SB force field (Hornak et 
al., 2006) was used to parameterise the protein; default protonation states were used: 
though there are suggestions that certain residues may exist at non-standard 
states,(Fahmy et al., 1993; Cherezov et al., 2007; Vanni, Neri, Tavernelli, & 
Rothlisberger, 2009; 2011) the ASP method is not expected to be sensitive to this as the 
residues in question (Asp2.50 and Glu3.41) are not in close proximity with the binding 
cavity and ASP particles are uncharged Lennard-Jones spheres, so it is unlikely that 
utilising the non-standard states would alter the strength of relevant interactions,. For all 
ASP runs the Cα-atoms of the protein were restrained to their initial positions with a 
force constant of 10.0 kcal/mol/Å2. ASP runs consisted of an initial energy 
minimisation step of 100 cycles, an equilibration molecular dynamics (MD) phase 
(between 0.2 and 2 ps), and finally the inflation phase with one ASP particle insertion 
step every 0.2 ps of dynamics (equal to 20 ps of MD in total for a run of 100 ASP 
cycles). Replicates (10 per system) of the ASP simulations differed only in the length of 
the initial equilibration phase. 
While these initial ASP studies were the ones that led to the discovery of the 
keyhole fissure that formed between helices 4 and 5, the non-selective pressurization of 
the whole ligand-binding cavity also led to other regions of the binding cavity, in 
particular the vital Asp3.32 and Asn7.39 side chains, adopting rotamers no longer 
conducive to ligand binding, having being pushed aside as the pocket filled with LJ 
particles. Therefore a focused ASP methodology was subsequently employed to 
specifically probe the keyhole region. This second application of ASP employed the 
original version of the algorithm, where a 14 x 10 x 10 Å grid was placed, covering the 
area from the inner edge of the conventional pocket to the outside of helices 4 and 5, 
encompassing the residues where movement involved in the formation of the fissure 
had previously been observed. The seed particle for this focused ASP grid corresponded 
with carazolol’s (1) carbazole nitrogen atom. All other parameters were the same as in 
previous ASP runs (four replicates per system). 
3. Docking 
Docking was carried out using Glide. (Friesner et al., 2004; Suite 2012: Glide, version 
5.8, Schrödinger, LLC, New York, NY, 2012) Structures of all ligands in Table 1 and 
Table 2 were drawn in Maestro’s 2D sketcher and prepared with LigPrep(Suite 2012: 
LigPrep, version 2.5, Schrödinger, LLC, New York, NY, 2012) to produce the S-
enantiomer carbinol group, and protonated nitrogen within the core ethanolamine (the 
additional chiral centre present in ICI-118,551 (7) was generated as both S and R). 
Crystal structures were imported and prepared minimally (processed, water removed, 
not refined) with Maestro’s protein preparation wizard. Using Glide, grids were 
produced based on the centre of carazolol (1) – this differed slightly depending on the 
crystal/model template; the relevant carazolol (1) molecule was used to select the centre 
for each grid. The grids each had a 10 Å3 inner box based around the carazolol (1) 
centre, with an outer box of 38 Å3. Docking of all previously crystallised antagonist 
ligands (Table 1) to our models was first performed with no constraints and in several 
cases yielded poor results with few poses reflecting crystallographic ligand placement. 
Subsequently, a core constraint was defined which required that ligands dock within 2.0 
Å of the ethanolamine heavy atoms of each model’s cognate carazolol (1) molecule. 
This constraint was successful in producing poses highly similar to crystallographic data 
for each ligand and was implemented for all future docking. Extended Sampling was 
turned on, for each ligand 50 poses were minimised post-docking and a maximum 20 
poses output. Default settings were used unless otherwise stated.   
4. Molecular Dynamics 
Selected ligand poses were refined using MD methods with AMBER 11.(Case et al., 
2005; Pearlman et al., 1995) For this work all the ligands in Table 2 along with 
carazolol (1) were parameterised using the AMBER Antechamber utility(J. Wang, 
Wang, Kollman, & Case, 2005), partial charges being calculated using the AMI-BCC 
method(Jakalian, Bush, Jack, & Bayly, 2000; Jakalian, Jack, & Bayly, 2002). The 
protein was parameterised as for the ASP studies. All complexes underwent a steepest 
decent minimisation for 50 cycles before switching to the conjugate gradient method 
until the convergence criterion of 0.1 kcal/mol-Å was reached. MD simulations were 
then run for 10 ns each, utilising a 2.0 fs time step and implementing the SHAKE 
algorithm for all bonds to hydrogen. Solvent was described implicitly via a generalised 
Born model (Onufriev model, igb=5).(Onufriev, Bashford, & Case, 2000; 2004) The 
membrane was not described since Amber 11 does not have an implicit membrane 
option; instead the seven transmembrane (TM) helical regions of the protein backbone 
were restrained (restraint weight 0.1 kcal/mol- Å2). A Langevin dynamics setting of 5ps 
-1 and a non-bonded cut off of 25.0 was used. The MMPBSA utility within Amber was 
employed to calculate MM-GBSA free energies of binding for each receptor-ligand 
complex over the course of each 10 ns simulation, sampling at intervals of 0.1 ns. 
Results 
1. Homology models 
Homology models were checked using PROCHECK(Laskowski, MacArthur, Moss, & 
Thornton, 1993) and Molprobity. (Davis et al., 2007) All models showed few outliers in 
Ramachandran plots (Supplementary Information Table S1); all of these outliers were 
found to be in intra- or extra-cellular loop regions far from the binding site. This finding 
is consistent with the template crystal structures, which also showed outliers, especially 
in the third intracellular loop. Due to the extremely high level of conservation between 
template binding sites (and subsequently models) we believe the models to be accurate 
enough for prediction of antagonist binding modes.  
2. Initial docking attempts  
When core constraints were used, we were able successfully to re-dock, using Glide, 
carazolol (1) and all other (Table 1) cognate ligands trialled to the 2RH1 and 2YCW 
crystal structures, as well as the homology models of both the 1- and 2-AR (Figure 
2a). H-bonding criteria were defined as a maximum H-X distance of 2.5 Å, a minimum 
donor angle of 90 ° and a minimum acceptor angle of 60 °. All top poses showed four 
H-bonds between the core ethanolamine and the conserved Asp3.32 and Asn7.39 residues. 
The top scoring pose for each ligand was in most cases nearest to the crystallographic 
pose, as defined by manual superimposition of previously aligned XRCs (See Figure 2a 
and Supplementary Information Table S2 for GlideScores). H-bonding to S228, 5.42 is not 
shown in the β1-AR model in Figure 2a (due to slightly unfavourable geometry, 
although proximity is good), but was seen in the β2-AR model, as with the XRC 
structures.  
However, when the same protocol was used for extended head group ligands 
(Table 2), we were unable to generate convincing poses consistently. In some cases the 
requirement that the core constraint be satisfied resulted in no docking poses at all being 
returned; when poses were produced they commonly exhibited fewer H-bonds between 
the ligand core ethanolamine and the Asp3.32 and Asn7.39 residues, and adopted either 
what we term ‘U-shaped’ or ‘reversed’ poses (See Supplementary Information Table S3 
for GlideScores). U-shaped poses (Figure 2b) are defined as a potential binding mode in 
an XRC or XRC-based model in which both the head and tail ends of the ligand are 
positioned towards the binding cavity entrance and extracellular surface of the -AR, 
often in solvent-accessible regions and not fully utilising the deeper, hydrophobic part 
of the binding cavity, which the head groups of all ligands in Table 1 occupy. Reversed 
poses (see Supplementary Information Figure S1) are defined as those in which the tail 
group is orientated towards the serine residues on H5, and the head group occupies the 
pocket entrance. 
U-shaped poses were produced for all extended ligands except CGP20712A (14) 
in the 2-AR model, but in the 1-AR model U-shaped poses were only obtained for LK 
204-545 (16) and esmolol (12), all other ligands failed to dock. In this docking mode, 
we typically saw the extended ligand head groups engage in H-bonding interactions 
with Asn6.55 (Figure 2b) or the backbone of Thr5.34 on ECL2, with the longer extensions 
terminating in the vicinity of Arg/Asp7.27 (1-AR Arg351, 2-AR Asp300) at the 
extracellular surface. The tail groups of the longer ligands LK 204-545 (16) and (15) 
made contacts with the backbone of Phe5.32 (situated in ECL2) in the 2-AR model, and 
the terminal hydroxyl group of LK 204-545 (16) H-bonded to Asp356, 7.32 in the 1-AR 
model. The equivalent of this latter interaction was not seen in the 2-AR as the residue 
at the corresponding position is Lys305, which forms a salt bridge with Asp192, 5.31 across 
the entrance to the binding pocket. 
Reversed poses were most commonly seen with CGP20712A (14), which failed 
to produce any canonical or U-shaped poses when core constraints were utilised, instead 
preferring to dock in this reversed orientation in both the crystal structures and 2-AR 
receptor model, and not at all in the 1-AR model or XRC. The bi-aryl nature of this 
ligand’s head group is inherently less flexible than the corresponding alkoxy head group 
of a ligand like LK 204-545 (16) or 15, so a U-shaped pose would not necessarily be 
expected/possible.  Reversed poses were not seen with LK 204-545 (16), despite its 
structural similarity to compound 15 for which a single reversed pose was produced in 
the 1-AR model when core constrains were removed (see Supplementary Information 
Figure S1). 
To explore the possibility that these extended ligands actually adopt a 
significantly different, but consistent binding pose compared to the established ligands, 
the docking procedure was repeated without the core constraints. The result was that the 
extended (Table 2) ligands rarely made contacts with the conventional binding site but 
instead showed interactions with residues at the edge of the pocket and extracellular 
surface, with major inconsistencies between poses adopted by structurally closely 
related ligands (such as the reversed pose seen for ligand 15 but not for LK 204-545 
(16)). The general absence of contacts deemed vital by SAR, mutation studies, and 
current structural knowledge from crystallography, suggested these non-core-constraint 
poses were unlikely to be valid.  
3. Active Site Pressurization 
ASP was applied to the homology models of both the 1- and 2-AR. In the first 
instance simulations were repeated ten times to assess the significance and 
reproducibility of structural perturbations that were observed. In the majority of cases, 
after an initial phase when the empty volume of the pocket was filled, ASP particles 
then pushed open a narrow fissure between H4 and H5 exposing the intra-membrane 
space (Figure 3). The fissure, which we have termed the ‘keyhole’, is formed by the 
adjustment of certain amino acid side-chain torsions with only minor adjustments to 
backbone atoms. In particular we observed movement of Tyr5.38, Ser5.42, Ser5.46, 
Val/Thr4.56, and to a smaller extent Pro4.50 (see Supplementary Information Tables S4 
and S5 for backbone Cα movement  distances and side chain χ1 dihedral angles pre- and 
post-ASP). The residues newly accessible to the binding pocket comprise generally 
hydrophobic transmembrane amino acids (as they are located in intra-membrane space) 
including Ala5.41, Val5.45 (this residue is Ile214 in the turkey 1-AR), as well as the indole 
ring of Trp4.35. 
 In order to check that this observation was not an artefact of the homology 
modelling process, it was also applied to the crystal structures (2RH1 and 2YCW) with 
very similar results. The ASP methodology was refined to retain the integrity of the 
main binding pocket, thus creating the keyhole without distorting the vital Asp3.32 and 
Asn7.39 side chains required for ligand binding. These simulations were repeated four 
times for each receptor, replicate runs varying in the length of the equilibration MD 
phase before ASP was begun (see Methods Section 2), in order to start from slightly 
varying initial structures and velocity distributions. We observed keyhole formation 
100% of the time for the 1-AR model, 50% of the time for the 2-AR model, 50% for 
the 2YCW (turkey '1-AR’ 36-m23) XRC structure, and 75% of the time for the 2RH1 
XRC structure. This suggests that keyhole formation from the 1-AR model was less 
affected by fine details of the starting conformation of the receptor and particle insertion 
process than was the 2-AR – features which may in turn relate to the entropic 
component of the free energy of keyhole formation in these two receptors. The model 
with the largest keyhole (defined visually in PyMOL (The PyMOL Molecular Graphics 
System, version 1.5.0.4, Schrödinger, LLC) using a surface representation with a default 
probe radius of 1.4 Å) was selected for each receptor to be used in post-ASP docking 
studies. 
4. Docking studies after ASP 
Glide was used to re-dock the extended ligands in Table 2: acebutolol (10), betaxolol 
(11), esmolol (12), bisoprolol (13), CGP20712A (14), (15) and LK 204-545 (16), to the 
1- and 2-AR models featuring the keyhole. For consistency with the earlier studies, 
these docking runs used the same restraints on core interactions (see Methods Section). 
Although not always a high-scoring pose (see Supplementary Information Table S6 for 
GlideScores), in several cases a model was obtained in which simultaneously the 
extended head group moiety was located in the keyhole region, whilst the ethanolamine 
core was involved in the canonical interactions with Asp3.32 and Asn7.39 (Figures 4 and 
5).  
Ligands LK 204-545 (16) and (15) differ only in the presence of a cyano 
substituent on the aromatic ring in the former, yet the result of this addition is a 
significant increase in 1-AR binding affinity (-log Kd increased from -7.59 to -8.38,  
see Table 2). The docked poses for these ligands provide a plausible explanation for this 
(Figure 5). We see that the cyano group is placed in close proximity to Asn6.55 and the 
possibility of a favourable hydrogen bonding interaction between these two would be 
enhanced even further if the asparagine were to adopt one of the alternative rotamers 
that have been observed experimentally in 1-AR crystal structures.(Laskowski et al., 
1993; Warne et al., 2011; 2012)  
5. Evaluation of U-shaped versus keyhole poses by molecular dynamics. 
To explore further the relative merits of the U-shaped versus keyhole pose options, 
selected models for all ligands in Table 2 in complex with both 1-AR and 2-AR 
receptors were refined using AMBER. As far as possible, all simulations began from 
poses generated from the docking procedures; where no suitable start-point was 
available, ligands were manually docked into the appropriate 1- or 2- model using 
data from cognate ligands in cognate protein models. The MD runs were stable and in 
all cases the ligand stayed within the pocket/keyhole while always retaining H-bonding 
contacts between the ligand core ethanolamine and the Asp3.32 and Asn7.39 clamp. See 
Supplementary Information Figure S2 for a summary of all -AR residues implicated in 
H-bonding interactions. 
5.1. H-bonding interactions between the ligand head/tail groups and the -ARs 
observed during MD 
a) The 1-AR models 
In addition to interactions with the core ethanolamine moiety,  interactions commonly 
maintained between the 1-AR models and ligands in U-shaped poses included H-
bonding between polar atoms in head group extensions and Asn6.55 (acebutolol (10), 
bisoprolol (13), betaxolol (11) and 15), Arg7.27 (acebutolol (10) and esmolol (12)), and 
the backbone of Thr5.34 (esmolol (12)), residues which were all seen to be involved in H-
bonding interactions in the original docking results. New H-bonding interactions 
between head groups and Lys6.58 (esmolol (12)) and the phenol of Thr5.34 (bisoprolol 
(13), betaxolol (11), esmolol (12), 15 and LK 204-545 (16)) were also observed during 
MD runs. The longer tail group of LK 204-545 (16) moved so as to create H-bonding 
opportunities between its urea carbonyl and Trp7.40, and as seen in the original docking, 
the phenolic oxygen was also occasionally able to accept an H-bond from the non-
conserved Arg7.33. Ligand 15, despite possessing a tail group identical to that of LK 
204-545 (16), failed to demonstrate any consistent H-bonding to/from its tail. 
In contrast, when ligands were bound to the 1-AR utilising the keyhole region, 
the same tail group showed interactions with the backbone of Phe5.32 (15 and LK 204-
545 (16)). Ligand 15 also made the additional H-bonds to the conserved residues 
Trp7.40, Asp7.31, Gly2.61, and Cys5.30 (backbone carbonyl). LK 204-545 (16) formed H-
bonds to Arg7.33 (seen in the original docking and U-shaped MD complexes) 
demonstrating that keyhole binding does not preclude this subtype-specific tail group 
interaction, which likely confers some of the 1-AR selectivity of this molecule. In the 
keyhole complexes the head groups of all extended ligands tended to H-bond directly 
with the keyhole residues Tyr5.38, Ser5.42, and Ser5.46. All ligands, at some stage in the 
simulation, showed an interaction with either Ser5.46 or Tyr5.38, acebutolol (10) 
interacting with both of these simultaneously, due to its amide moiety (other ligands 
contain ether or ester moieties in the corresponding position). 
b) The 2-AR models 
In the 2-AR model the U-shaped poses showed head groups interacting with Thr5.34 
(side chain and backbone) and Asn6.55, as with the 1-AR. The ether moiety of esmolol 
(12) showed a brief interaction with the non-conserved Tyr7.35 (Phe359 is the 
corresponding residue in the 1-AR), but no equivalent to this ligand’s interaction with 
Lys6.58 in the 1-AR was seen in the 2-AR (where the corresponding residue is His296). 
The phenolic oxygen atom in the tail group of 15 occasionally interacted with Trp7.40. 
LK 204-545 (16) exhibited consistent interactions between its tail group urea moiety 
and the conserved Asp5.31 in ECL2, potentially disrupting (or augmenting) the salt 
bridge formed by this residue with Lys7.32 in the 2-AR.  
The 2-AR keyhole complexes also showed consistent H-bonding interactions 
between ligand head groups and Tyr5.38, Ser5.42, and Ser5.46. In the keyhole–LK 204-545 
(16) complex tail group interactions with Lys7.32 (Asp356 in the 1-AR), Asp5.31, Cys5.30 
and His2.64 (Ile118 in the 1-AR) were observed. The keyhole-15 complex showed 
interactions between Trp7.40 and Gly2.61 and this ligand’s tail group.  
It is now generally accepted that the variability of the extracellular receptor 
surface is responsible for the different binding profiles of antagonists between these the 
-AR subtypes (including turkey 1-AR versus human 1-AR). Binding and 
dissociation studies pay particular attention to the 1-AR subtype specific Glu205 
(ECL2) – Arg351,7.27 salt bridge (not observed in turkey 1-AR as Glu205 is Gln188 in this 
subtype and is between 3.5 – 10 Å away from Arg7.27 in XRC structures) and the 2-AR 
specific Asp193,5.31 – Lys305,7.32 salt bridge, the latter of which spans the entrance to the 
binding cavity of the 2-AR, hindering unbinding and stabilising the inactive 
conformation of the 2-AR(Bokoch et al., 2010; Davis et al., 2007; González, Perez-
Acle, Pardo, & Deupi, 2011; Selvam, Wereszczynski, & Tikhonova, 2012). Although 
we observe the tail groups of the ligands LK 204-545 (16) and 15 interacting with the 
Lys/Asp salt bridge at the entrance of the 2-AR pocket, it is not obvious which of the 
observed binding modes is most likely. We observed ligand tail groups positioned either 
side of the salt bridge, occasionally interacting with Lys7.32 or Asp5.32 directly. 
Interestingly these same tail groups showed interactions with the equivalent residue to 
Lys7.32 on the 1-AR (Asp 356,7.32) as well as with the conserved Asp 5.32, and 
additionally with Arg 351,7.27 of the 1-AR salt bridge. Variations of placement of the 
methoxyphenyl tail group of full agonist carmoterol are seen in monomer A and B of 
the 1-AR crystal containing this ligand (due to a crystal contact in monomer A), 
suggesting that very small variations in backbone conformation can result in 
maintenance of the core ethanolamine binding site (and allow the core to dock) whist 
significantly affecting ligand tail placement. Our data suggest that tail groups have more 
freedom of movement generally as they tend to be orientated towards the extracellular 
entrance to the binding pocket, and do not stay anchored to a particular contact but 
move between several HBA/HBDs. Tail groups clearly play an important role in 
selectivity, due to their ability to make interactions with non-conserved extracellular 
surface residues. 
5.2. Energetic analysis of alternative binding models 
Using data from the last 10 ns of the simulation of each protein-ligand complex, the 
Amber11 MM-GBSA method was used to estimate free energies of binding. The results 
are shown in Table 3. The β1-AR model containing the U-shaped betaxolol (11) pose 
failed to give a realistic free energy measure due to an unreasonably high VdW term 
(clashes between the ligand and receptor). CGP20712A (14) is not included in the data 
set as no U-shaped poses could be generated for this ligand. 
   
Table 3. Energetic comparison of U-shaped and keyhole poses in -ARs. 
Ligand 
U-shaped pose Keyhole pose 
β1-AR 
model 
SEMb 
β2-AR 
model 
SEM 
β1-AR 
model 
SEM 
β2-AR 
model 
SEM 
Acebutolol (10) -32.38 0.55 -45.41 0.47 -53.83 0.43 -56.13 0.44 
Betaxolol (11) - - -47.00 0.60 -57.32 0.56 -62.03 0.44 
Bisoprolol (13) -56.47 0.58 -60.68 0.74 -61.57 0.46 -66.58 0.40 
Esmolol (12) -44.16 0.40 -49.46 0.47 -48.69 0.43 -50.89 0.52 
LK 204-545 (16) -64.53 0.61 -60.53 0.56 -64.19 0.59 -70.00 0.55 
15 -61.66 
0.50 -65.45 0.63 -64.40 0.54 -70.49 0.42 
aMM-GBSA estimations of the free energy of binding for each complex. Energies in 
kcal/mol. 
bSEM; standard error of the mean. SEM is used as the data from each snapshot of the 
simulation is considered when computing the MM-GBSA free energy estimation. 
 
While, experimentally, all these ligands are 1-AR-selective  (Baker, 2005; Benfield & 
Sorkin, 1987; S. N. S. Louis, Nero, Iakovidis, Jackman, & Louis, 1999; Mistry et al., 
2013), the MM-GBSA free energies of binding are almost always more favourable for 
the 2-AR. Though this suggests the approach has neglected an isoform-specific energy 
term, it does not alter the key observation that the MM-GBSA scores clearly support the 
idea that the keyhole poses are more favourable energetically. In fact, the only case 
where a U-shaped pose scores more highly than a keyhole pose is in the case of the 1-
AR model complexed with LK 204-545 (16), but the difference is not significant when 
the standard error of the mean is considered. The relative energetic cost of creating a 
keyhole in  1-AR  versus 2-AR may also play a role in selectivity, but this cannot be 
reported quantitatively here as the bulk solvent terms that come with the use of implicit 
solvent (as was the case for all ASP and subsequent MD studies) results in an energetic 
analysis that contains insufficient detail; we do note though (see section 3 above) that 
keyhole formation using ASP appears easier to initiate from the closed state of the 1-
AR than the 2-AR. 
 
Discussion 
The application of the ASP process to both crystal structures and homology models of 
1- and 2-ARs provides clear support for our hypothesis that the ligand binding cavity 
has the necessary plasticity to accommodate ligands bearing longer head groups than 
are present in any of the structures crystallised to date, without the need to propose a 
radically different binding mode. Remarkably, the ‘keyhole’ revealed by ASP, located 
between TM H4 and H5, is ideal in terms of location, size and chemical composition to 
accommodate these extended ligands. The polar groups (often ethers) of all ligands with 
extended head groups are well placed to engage in polar interactions and H-bonds with 
Ser 5.42, Ser 5.46 and Tyr 5.38 which line the keyhole, while the terminal isopropyl or 
cyclopropyl group occupies a hydrophobic patch at the surface of the protein in the 
intra-membrane space. These hydrophobic interactions are maximized in the 1-AR 
subtype due to the valine residue at position 4.56, which lines the keyhole; a polar 
threonine residue exists at this position in the 2-AR subtype.  
Additional evidence for ‘keyhole’ formation at the H4/H5 interface in the -ARs 
has come from molecular dynamics studies by other authors who have investigated 
binding and unbinding of ligands from GPCRs. Wang and Duan have used RAMD 
simulations to predict the exit pathway of carazolol (1) from the 2-AR (T. Wang & 
Duan, 2009). The authors identify a pathway between H4 and H5 as the second most 
common egress route, second only to the extracellular surface opening (carazolol (1) 
used this route 20% and 27% of the time in the two data sets). In a separate study by the 
same authors, this point of egress was also seen as the primary exit pathway for the 
ligand retinal in simulations of inactive bovine rhodopsin (T. Wang & Duan, 2007) 
Other intra-membrane egress pathways (between H1 and H7, and between H5 and H6) 
have also been determined for the ligand-free opsin,(Hildebrand et al., 2009; T. Wang & 
Duan, 2009) but were not observed in the -ARs.(González et al., 2011; T. Wang & 
Duan, 2007) An impressive study of spontaneous binding of several -blockers to the 
2-AR from 82 MD simulations between 1-19 μs in length, did not show any of the 
ligands actually entering the binding pocket via an intra-membrane route, but confirmed 
the results of other dynamical studies which identified the extracellular opening as the 
route of ligand entry(Dror et al., 2011; Hildebrand et al., 2009).  
All crystal structures of the -ARs exhibit only moderate-weak hydrophobic 
interactions at this helical interface, and although not always as large as the keyhole 
produced by ASP, 12 of the 32 currently availably -AR XRCs display a cavity or hole 
in the binding pocket wall at this position (see Supplementary Information Table S7). 
We also know that there is a great deal of conformational flexibility possible in the area 
of the keyhole associated with receptor activation - 2-AR structures show a 2.1 Å 
movement of the Cα of Ser 
5.46 when agonist and antagonist structures are compared (a 
difference of ~1 Å in the 1-AR turkey structures(González et al., 2011; Warne et al., 
2011)). We also observe various rotamer states of Ser 5.46 depending on whether it can 
directly H-bond to the ligand occupying the binding site, so our hypothesis that a 
keyhole can form in this region seems plausible.  
Intriguingly, the apo crystal structure shows H4/H5 crystal contacts that 
juxtapose the keyholes of each protein (see Figure 6). Thus our docking findings 
suggest a possible novel binding mode for bivalent ligands.(Dror et al., 2011; Valant, 
Robert Lane, Sexton, & Christopoulos, 2012) 
The keyhole hypothesis does not provide a complete rationalisation of the 1-AR 
selectivity for all extended ligands, as both 1- and 2-AR subtypes appear capable of 
producing this feature. However there are subtle differences between subtypes in the 
geometry and chemical composition of the keyhole due to the non-conserved 
Val/Thr4.56. Previous studies on the potential impact of the 2 Thr186 4.56Ile genetic 
polymorphism have argued that this mutation will impact on water-mediated hydrogen 
bonding between Ser165,4.55, Ser207,5.46 and this amino acid, making the interactions in 
this region more similar to those in 1-AR(Warne et al., 2011). Intriguingly, a water 
molecule can be found in or near to the keyhole region of several of the current 1-AR 
XRC structures to date. (Christopher et al., 2013; Miller-Gallacher et al., 2014; Warne 
et al., 2012) 
How these findings can be used to rationalise -AR SAR remains to be fully 
explored. It is known that subtype selectivity involves a complex cross talk between 
features in both the head and tail moieties. It may be that slight differences in how the 
molecules occupy the pocket, enforced by the constraints of the narrow keyhole region, 
alter the effectiveness of interactions between the tail extensions and key functional 
groups in the receptors. The current understanding is that the mechanism by which 
ligands enter the -ARs is different between subytpes.(Dror et al., 2011) This is likely 
the case, when they share such conserved binding pockets but show such diverse 
pharmacology for ligands such as those discussed in this paper. It may be that the 
method by which ligands enter the 1AR is conducive to the formation of the keyhole, 
allowing extended ligands to utilise this feature on docking, or as an allosteric site. This 
fits with the known pharmacology, as a change in the residue lining the keyhole at 
position 4.56 from Val to Thr would result in a more polar keyhole region which may 
be occluded by water, forcing the hydrophobic head group extensions to adopt U-
shaped poses rather than occupy the keyhole.  
The plasticity of ligand binding sites in proteins is well appreciated and attempts 
to predict the modes of binding of new ligands to known receptors can depend critically 
on adequately sampling this. The -ARs are no exception; at a ‘micro’ level, Ser5.42, 
Ser5.46 and Asn6.55, have each been shown to adopt alternative rotamer states depending 
on the ligand co-crystallised.(Valant et al., 2012; Warne et al., 2011; 2012) Larger 
ligands, such as those studied here, can be expected to bring about more drastic 
adaptations in protein structure. An example can be seen when comparing the A2A 
structures crystallised with agonists adenosine(Lebon et al., 2011; Warne et al., 2011) 
and UK432097,(Warne et al., 2011; 2012; Xu et al., 2011) the latter of which induced a 
3.8 Å widening of the binding pocket mouth due to extracellular loop 
rearrangement.(Lebon et al., 2011; Tate, 2012) The ability of computational methods to 
predict such adaptions has obvious importance when crystal structures remain, at times, 
elusive, and additionally is a valuable resource when there is a wish to think “outside 
the box” of existing structural data for the design of novel ligands. 
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Figure 1. Schematic of the conventional β-AR antagonist ligand-binding site. The 
orthosteric binding pockets of β1- and β2-ARs are almost identical. Residues within 4 Å 
of an antagonist ligand template are shown. The only difference evident is at position 
7.35 (Ballesteros-Weinstein numbering), where Phe359 in β1-AR is replaced by Tyr308 in 
β2-AR. Dashed lines represent ligand-specific interactions (see text for details). 
 
 Figure 2. Conventional and U-shaped docking poses in the β1-AR model. (a) Carazolol 
(1) (yellow) docked to the β1-AR model (grey helices) in good agreement with the 
2YCW crystal carazolol (1) placement (thin blue structure). (b) LK 204–545 (16) 
exhibiting a U-shaped pose with both the head and tail ends of the molecule in solvent-
accessible regions. The tail group may confer selectivity by interacting with non-
conserved residue D356,7.32 (K305,7.32 in β2-AR). In both (a) and (b) the extracellular ends 
of H2 and H3 have been removed for clarity and ECL2 and H1 are not shown. Side 
chain and ligand carbon atoms are coloured green and yellow, respectively. Polar 
hydrogens are white, nitrogen atoms are coloured blue and oxygen atoms red. Potential 
H-bonding is indicated with yellow dashed lines with the exception of the interhelical 
H-bond between Tyr367 and Asp138, which is displayed as a purple dashed line. The β1-
AR residue numbering is displayed for highlighted polar residues with Ballesteros-
Weinstein numbering in superscript. 
 
 
Figure 3. The Active Site Pressurisation (ASP) process. The schematics (a)–(c) 
represent the ASP process whereby non-charged Lennard-Jones particles (red spheres) 
fill up the binding pocket over the course of an MD simulation. The initial filling (a) 
packs the receptor (grey) cavity; it is a dynamic process so subsequent particles are 
added where receptor plasticity exists (b). Side chains continue to move creating further 
space for particles to fill; in some cases channels are formed (c). (d) Shows the β1-AR 
model surface of H4 and H5 before ASP, (e) is the same view after ASP and depicts the 
size and location of the keyhole. The residues Tyr5.38, Ser5.42, Ser5.46, Val4.56 and Pro4.50, 
which line the keyhole, are coloured red in both cases. (f) Shows the β1-AR model in 
the final stages of the ASP process and the red Lennard–Jones particles (1.1 Å radius) 
protruding outwards having broken the integrity of the cavity wall between H4 and H5 
(highlighted by the yellow circle). (g) Is the same as (f ) but rotated about the y axis by 
−90° to show the location of the cavity breach. 
 Figure 4. “Top” and “side” views of the β1-AR cavity before and after Active Site 
Pressurisation and the extended head group of LK 204-545 (16) docked through the 
keyhole of the β1-AR model. (a) and (c) show the original β1-AR model (prior to ASP), 
with carazolol (1) docked into the pocket. (b) and (d) show the β1-AR model after it has 
been subjected to ASP and a narrow fissure has formed between H4 and H5. In (a) and 
(b) the extracellular surface of the receptor has been clipped away to reveal the pocket 
shape at the depth of carazolol’s (1) chiral carbinol (this plane is represented by the red 
dashed line in (c) and (d)). (c) and (d) represent a vertical slice along the extracellular to 
intracellular length of the receptor (also indicated by the red dashed line in (a) and (b)). 
(b) and (d) show the capability of the keyhole to accommodate the extended head group 
of ligands such as LK 204-545 (16). The carbon atoms of carazolol (1) and LK 204-545 
(16) are coloured yellow. Polar hydrogens are white, nitrogen atoms are blue and 
oxygen atoms red. 
 Figure 5. The extended head group of LK 204-545 (16) docked through the keyhole of 
the β1-AR model. This figure indicates the position of LK 204-545 (16) in relation to 
key binding pocket residues. Canonical interactions are observed between the 
ethanolamine core of the ligand and Asp3.32 and Asn7.39 while the extended head group is 
positioned between H4 and H5 – the alkyl ether engages in polar interactions with 
Ser5.42 (note new rotamer state due to ASP) while the cyclopropyl tail occupies the intra-
membrane space. Colouring and representations are the same as for Figure 2. Note the 
vicinity of Asn6.55 to the ligand nitrile group – if this residue were to adopt a different 
rotamer state (see partially transparent pre-ASP rotamer) an interaction with the ligand 
may be possible. 
 Figure 6. Aligned keyholes at the H4/H5 dimer interface found in the oligomeric ligand-
free turkey β1-AR structure. (a) Depicts the dimer interface of two turkey β1-ARs (PDB 
code 4GPO; Huang et al., 2013), with keyhole residues shown in a surface 
representation. (b) Depicts the dimer interface opened up and each monomer rotated 90° 
revealing two aligned keyholes. 
